TY - JOUR
T1 - Perspectives in immunotherapy
T2 - meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy)
AU - Ascierto, Paolo A.
AU - Bifulco, Carlo
AU - Ciardiello, Fortunato
AU - Demaria, Sandra
AU - Emens, Leisha
AU - Ferris, Robert
AU - Formenti, Silvia C.
AU - Galon, Jerome
AU - Khleif, Samir N.
AU - Kirchhoff, Tomas
AU - McQuade, Jennifer
AU - Odunsi, Kunle
AU - Patnaik, Akash
AU - Paulos, Chrystal M.
AU - Taube, Janis M.
AU - Timmerman, John
AU - Fox, Bernard A.
AU - Hwu, Patrick
AU - Puzanov, Igor
N1 - Funding Information:
Paolo A. Ascierto (PAA): Consulting fee: BMS, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Newlinks Genetics, Genmab, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandox, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore. Contracted Research: BMS, Roche, Array. Travel Support: MSD. Carlo Bifulco (CB): Scientific Advisory Board & Stock Ownership: PrimeVax, BioAI. Patent US20180322632A1: Image processing systems and methods for displaying multiple images of a biological specimen. Fortunato Ciardiello (FC): Receipt of honoraria or consultation fees for speaker, consultancy or advisory roles: Amgen, Bayer, Bristol-Myers Squibb, Celgene, Merck Serono, Pfizer, Roche, Servier—Direct research funding as the principal investigator for institutional research projects: Amgen, Bayer, Merck Serono, Roche, Ipsen—Institutional financial interests, financial support for clinical trials or contracted research: Merck Serono, Roche, Symphogen, Array. Sandra Demaria (SD): has received research support from Lytix Biopharma, and consultant fees from Lytix Biopharma and Ono Pharmaceuticals. Leisha A. Emens (LAE): Research Funding: Aduro Biotech, Astrazeneca, Bolt Therapeutics, Breast Cancer Research Foundation, Bristol Meyers Squibb, Compugen, Corvus, CyTomX, Department of Defense, EMD Serono, Genentech, HeritX, Inc., Maxcyte, Merck, National Cancer Institute, NSABP Foundation, Roche, Stand Up to Cancer, Silverback, Tempest, Takeda, Translational Breast Cancer Research Consortium—Consulting Fees: AbbVie honoraria, Amgen honoraria, Astrazeneca honoraria /travel/accommodation/expenses, Bayer honoraria/travel/accommodation/expenses, Bristol Meyers Squibb travel/accommodation/expenses, Celgene honoraria, Chugai honoraria, Genentech honoraria/travel/accommodation/expenses, GCPR honoraria, Gilead honoraria, Gritstone honoraria, Medimmune honoraria, Molecuvax (potential for stock in future), Macrogenics honoraria + travel/accommodation/expenses, Novartis travel/accommodation/expenses, Peregrine honoraria, Replimune honoraria + travel/accommodation/expenses, Roche honoraria + travel/accommodation/expenses, Shionogi honoraria, Silverback no compensation, Syndax honoraria, Vaccinex honoraria + travel/accommodation/expenses, Royalties: Aduro Biotech. Robert Ferris (RF): AstraZeneca/Medimmune: clinical trial, research funding—Bristol-Myers Squibb: advisory board, clinical trial, research funding – EMD Serono/MacroGenics Inc/Numab Therapeutics AG/Pfizer: advisory board – Merck: advisory board, clinical trial – Novasenta: consulting, stock, research funding – Tesaro: research funding. Silvia C. Formenti (SCF): nothing to declare. Jerome Galon (JG): has patents associated with the immune prognostic biomarkers. JG is co-founder of HalioDx biotech company. Immunoscore® a registered trademark from the National Institute of Health and Medical Research (INSERM) licensed to HalioDx. Samir N. Khleif (SNK): Owner/Founder: Georgiamune, LLC—Board Member: Advaxis Board of Directors—Consultant/Advisory Board: Amoon, Adaptive Biotechnology, AratingaBio Inc, AstraZeneca, Aummune, Bioline Therapeutics, Cancer Panels, LLC, CanImGuide Therapeutics, Coherus, Cytomex, Hikma Pharmaceuticals, Incyte, IOBiotechnology, Israel Biotech Fund GP Partners, KAHR Medical, Livzon Mabpharm USA, Lycera, McKinsey Health, Merck, Nectin TX, Northwest Biotherapeutics, PDS Biotechnology, Repare, Syndax, Tessa Therapeutics, UbiVac—Research Support: AstraZeneca, BioLine Therapeutics, Bristol-Myers Squibb, HeatBio, IO Biotechnologies, KAHR Medical, Lycera, MediImmune, Merck, Pelican Therapeutics, Syndax – Stock: Advaxis, Immunotherapy, Princeton, NJ Northwest Biotherapeutics, Bethesda, MD, PDS Biotechnology, North Brunswick Township, NJ, IO Biotechnology, Copenhagen, KAHR Medical, Israel. Tomas Kirchhoff (TK): nothing to declare. Jennifer McQuade (JMQ): consulting: BMS, Merck, Roche. Kunle Odunsi (KO): is a co-founder of Tactiva Therapeutics and receives research support from AstraZeneca and Tesaro. Akash Patnaik (AP): has received laboratory research support from Bristol Myers Squibb. In addition, he has received clinical trial funding support from Clovis Oncology, Bristol Myers Squibb and Progenics Inc. Dr. Patnaik has served on advisory boards for Janssen Pharmaceuticals, Exelixis Inc. and Jounce Therapeutics Inc., over the past 3 years. Chrystal M. Paulos (CMP): Ares Immunotherapy, ThermoFisher, Lycera, Obsidian. Janis M. Taube (JMT): serves as a consultant/advisory board member for BMS, Merck, Astra Zeneca, Compugen, and Akoya Biosciences. Dr. Taube also receives reagents, instrument loan, and stock options from Akoya Biosciences. John Timmerman (JT): Kite/Gilead, Bristol-Myers Squibb, Merck, Spectrum Pharmaceuticals, Celgene. Bernard A. Fox (BAF): Scientific Advisory Board (Advising/Consulting/Stock): Akoya/PerkinElmer, AstraZeneca / MedImmune, Bayer, Bristol-Myers Squibb, CellDex Therapeutics, Definiens, Incyte, Janssen /Johnson & Johnson, Macrogenics, PrimeVax—stock, Turnstone, UbiVac—Co founder/CEO/stock, Ultivue—Research Support: Akoya/PerkinElmer, Bayer, Bristol-Myers Squibb, Definiens, Janssen / Johnson & Johnson, Macrogenics, MedImmune/AstraZeneca, NanoString, OncoSec, Quanterix, Shimadzu, Ventana/Roche, Viralytics/Merck. Patrick Hwu (PH): Scientific Advisory Board: Immatics US, Inc., Dragonfly, GlaxoSmithKline, Sanofi Pasteur. Igor Puzanov (IP): Amgen-consultant fees, steering committee member KEYNOTE 265; Merck-advisory board fees; Sotio-consultant fees; Celldex-private stock ownership. Institutional Clinical Trial Support: Nektar, Idera, Oncosec, Amgen, Rgenix, Immunocore, Dynavax.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with different tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a significant proportion of patients still fail to benefit from current immunotherapy options, and ongoing research is focused on transforming non-responders to responders through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identification of biomarkers of response. These topics were the focus of the virtual Immunotherapy Bridge (December 2nd–3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.
AB - Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with different tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a significant proportion of patients still fail to benefit from current immunotherapy options, and ongoing research is focused on transforming non-responders to responders through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identification of biomarkers of response. These topics were the focus of the virtual Immunotherapy Bridge (December 2nd–3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.
KW - Biomarkers
KW - Checkpoint inhibitors
KW - Combination therapy
KW - Immunotherapy
KW - Tumor microenvironment
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85107224369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107224369&partnerID=8YFLogxK
U2 - 10.1186/s12967-021-02895-2
DO - 10.1186/s12967-021-02895-2
M3 - Article
C2 - 34078406
AN - SCOPUS:85107224369
SN - 1479-5876
VL - 19
JO - Journal of translational medicine
JF - Journal of translational medicine
IS - 1
M1 - 238
ER -